CIK 0001863127 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Tyra Biosciences, Inc.
Sign in to watch- Ticker
- TYRA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 831476348
- Phone
- (619) 728-4760
- Business address
- 2656 STATE STREET, CARLSBAD, CA, 92008
- Open-market buys, last 90 days
- $20,000
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$20,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 72 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-05 | Rueb Yuliya Vice President, Finance (PAO) | Grant or award | +8,333 | 43,354 | ||
| 2026-05-05 | Rueb Yuliya Vice President, Finance (PAO) | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2026-04-16 | Dable Habib J Director | Grant or award · Stock Option (Right to Buy) | +44,400 | 44,400 | ||
| 2026-03-26 | KAPLAN GILLA Director | Option exercise | −53,172 | $2.25 | $120K | 81,403 |
| 2026-03-26 | KAPLAN GILLA Director | Returned to the company | −53,172 | $37.75 | $2.0M | 28,231 |
| 2026-03-26 | KAPLAN GILLA Director | Option exercise · Stock Option (Right to Buy) | −53,172 | 0 | ||
| 2026-03-25 | KAPLAN GILLA Director | Option exercise | +14,295 | $2.25 | $32K | 42,526 |
| 2026-03-25 | KAPLAN GILLA Director | Sale | −14,295 | $36.97 | $529K | 28,231 |
| 2026-03-25 | KAPLAN GILLA Director | Option exercise · Stock Option (Right to Buy) | −14,295 | 53,172 | ||
| 2026-03-13 | Fuhrman Alan Chief Financial Officer | Grant or award | +1,376 | $9.13 | $13K | 16,164 |
| 2026-03-13 | Harris Todd President and CEO | Grant or award | +1,463 | $9.13 | $13K | 1,358,631 |
| 2026-02-12 | Bensen Daniel Chief Discovery Officer | Sale 10b5-1 | −2,128 | $31.50 | $67K | 152,853 |
| 2026-02-12 | Bensen Daniel Chief Discovery Officer | Sale 10b5-1 | −5,872 | $33.37 | $196K | 146,981 |
| 2026-01-12 | Bensen Daniel Chief Discovery Officer | Sale 10b5-1 | −6,983 | $28.44 | $199K | 155,998 |
| 2026-01-12 | Bensen Daniel Chief Discovery Officer | Sale 10b5-1 | −1,017 | $29.08 | $30K | 154,981 |
| 2025-12-19 | MORE ROBERT J Director | Sale 10b5-1 | −10,000 | $25.00 | $250K | 3,823,425 |
| 2025-12-12 | Bensen Daniel Chief Discovery Officer | Sale 10b5-1 | −8,000 | $22.64 | $181K | 162,981 |
| 2025-12-01 | Ashar Bhavesh Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2025-11-21 | MORE ROBERT J Director | Sale 10b5-1 | −246,871 | $20.25 | $5.0M | 3,833,425 |
| 2025-11-19 | Bensen Daniel Chief Operating Officer | Sale 10b5-1 | −49,956 | $16.32 | $815K | 170,981 |
Page 2 of 9 · 170 trades